Chris T Longenecker1, Corrilynn O Hileman2, Nicholas T Funderburg3, Grace A McComsey1. 1. Case Western Reserve University School of Medicine University Hospitals Case Medical Center. 2. Case Western Reserve University School of Medicine MetroHealth Medical Center, Cleveland. 3. The Ohio State University School of Health and Rehabilitation Sciences, Columbus.
Abstract
BACKGROUND: In chronic human immunodeficiency virus (HIV) infection, plasma cystatin C may be influenced by factors other than glomerular filtration rate such as inflammation. Statins may improve cystatin C by improving glomerular function or by decreasing inflammation. METHODS: The Stopping Atherosclerosis and Treating Unhealthy Bone With Rosuvastatin in HIV (SATURN-HIV) trial randomized 147 patients on stable antiretroviral therapy (ART) withlow-density lipoprotein cholesterol ≤130 mg/dL to blinded 10 mg daily rosuvastatin or placebo. We analyzed relationships of baseline and 0- to 24-week changes in plasma cystatin C concentration with measures of vascular disease, inflammation, and immune activation. RESULTS:Median age was 46 (interquartile range, 40-53) years; 78% were male, 68% African American. Tenofovir and protease inhibitors were used in 88% and 49% of subjects, respectively. Baseline cystatin C was associated with higher carotid intima-media thickness and epicardial adipose tissue independent of age, sex, and race. Biomarkers of endothelial activation and inflammation were associated with cystatin C in a multivariable model independent of creatinine-based estimated glomerular filtration rate (eGFRcr). After 24 weeks, statin use slowed mean eGFRcr decline (1.61 vs -3.08 mL/minute/1.73 m(2) for statin vs placebo; P = .033) and decreased mean cystatin C (-0.034 mg/L vs 0.010 mg/L; P = .008). Within the statin group, changes in cystatin C correlated with changes in endothelial activation, inflammation, and T-cell activation. CONCLUSIONS:Rosuvastatin 10 mg daily reduces plasma cystatin C and slows kidney function decline in HIV-infected patients on ART. Reductions in cystatin C with statin therapy correlate with reductions in inflammatory biomarkers. Relationships between cystatin C, kidney function, and cardiovascular risk in HIV may be mediated in part by inflammation. Clinical Trials Registration. NCT01218802.
RCT Entities:
BACKGROUND: In chronic human immunodeficiency virus (HIV) infection, plasma cystatin C may be influenced by factors other than glomerular filtration rate such as inflammation. Statins may improve cystatin C by improving glomerular function or by decreasing inflammation. METHODS: The Stopping Atherosclerosis and Treating Unhealthy Bone With Rosuvastatin in HIV (SATURN-HIV) trial randomized 147 patients on stable antiretroviral therapy (ART) with low-density lipoprotein cholesterol ≤130 mg/dL to blinded 10 mg daily rosuvastatin or placebo. We analyzed relationships of baseline and 0- to 24-week changes in plasma cystatin C concentration with measures of vascular disease, inflammation, and immune activation. RESULTS: Median age was 46 (interquartile range, 40-53) years; 78% were male, 68% African American. Tenofovir and protease inhibitors were used in 88% and 49% of subjects, respectively. Baseline cystatin C was associated with higher carotid intima-media thickness and epicardial adipose tissue independent of age, sex, and race. Biomarkers of endothelial activation and inflammation were associated with cystatin C in a multivariable model independent of creatinine-based estimated glomerular filtration rate (eGFRcr). After 24 weeks, statin use slowed mean eGFRcr decline (1.61 vs -3.08 mL/minute/1.73 m(2) for statin vs placebo; P = .033) and decreased mean cystatin C (-0.034 mg/L vs 0.010 mg/L; P = .008). Within the statin group, changes in cystatin C correlated with changes in endothelial activation, inflammation, and T-cell activation. CONCLUSIONS:Rosuvastatin 10 mg daily reduces plasma cystatin C and slows kidney function decline in HIV-infectedpatients on ART. Reductions in cystatin C with statin therapy correlate with reductions in inflammatory biomarkers. Relationships between cystatin C, kidney function, and cardiovascular risk in HIV may be mediated in part by inflammation. Clinical Trials Registration. NCT01218802.
Authors: Giovanni F M Strippoli; Sankar D Navaneethan; David W Johnson; Vlado Perkovic; Fabio Pellegrini; Antonio Nicolucci; Jonathan C Craig Journal: BMJ Date: 2008-02-25
Authors: Marcello Tonelli; Chris Isles; Timothy Craven; Andrew Tonkin; Marc A Pfeffer; James Shepherd; Frank M Sacks; Curt Furberg; Stuart M Cobbe; John Simes; Malcolm West; Chris Packard; Gary C Curhan Journal: Circulation Date: 2005-07-05 Impact factor: 29.690
Authors: Marian Goicoechea; Soledad García de Vinuesa; Vicente Lahera; Victoria Cachofeiro; Francisco Gómez-Campderá; Almudena Vega; Soraya Abad; José Luño Journal: J Am Soc Nephrol Date: 2006-12 Impact factor: 10.121
Authors: Paul M Ridker; Eleanor Danielson; Francisco A H Fonseca; Jacques Genest; Antonio M Gotto; John J P Kastelein; Wolfgang Koenig; Peter Libby; Alberto J Lorenzatti; Jean G MacFadyen; Børge G Nordestgaard; James Shepherd; James T Willerson; Robert J Glynn Journal: N Engl J Med Date: 2008-11-09 Impact factor: 91.245
Authors: Chris T Longenecker; Rebecca Scherzer; Peter Bacchetti; Cora E Lewis; Carl Grunfeld; Michael G Shlipak Journal: AIDS Date: 2009-06-01 Impact factor: 4.177
Authors: Andy I Choi; Yongmei Li; Steven G Deeks; Carl Grunfeld; Paul A Volberding; Michael G Shlipak Journal: Circulation Date: 2010-01-25 Impact factor: 29.690
Authors: Edgar T Overton; Amy Kantor; Kathleen V Fitch; Paul Muntner; Khuanchai Supparatpinyo; Mosepele Mosepele; Lerato Mohapi; Sandra Wagner Cardoso; Sandesh Patil; Marcus V G de Lacerda; Grace McComsey; Judith A Aberg; Pamela S Douglas; Steven K Grinspoon; Heather Ribaudo; Christina M Wyatt Journal: J Infect Dis Date: 2020-07-09 Impact factor: 5.226
Authors: Sahera Dirajlal-Fargo; Bruce Kinley; Ying Jiang; Chris T Longenecker; Corrilynn O Hileman; Sara Debanne; Grace A McComsey Journal: AIDS Date: 2015-01-28 Impact factor: 4.177
Authors: Chris T Longenecker; Seunghee Margevicius; Yiying Liu; Mark D Schluchter; Chun-Ho Yun; Hiram G Bezerra; Grace A McComsey Journal: Am J Cardiol Date: 2017-07-24 Impact factor: 2.778
Authors: Simon B Ascher; Rebecca Scherzer; Arvind Nishtala; Vasantha Jotwani; Carl Grunfeld; Chirag R Parikh; Derek Ng; Ruibin Wang; Frank J Palella; Michael G Shlipak; Michelle M Estrella Journal: J Acquir Immune Defic Syndr Date: 2019-10-01 Impact factor: 3.731
Authors: Corrilynn O Hileman; Randi Turner; Nicholas T Funderburg; Richard D Semba; Grace A McComsey Journal: AIDS Date: 2016-01-02 Impact factor: 4.177